Preclinical studies have demonstrated that blocking both TIGIT and PD-1 significantly enhances tumor-specific T cell proliferation, degranulation, and cytokine production (64).The adverse reactions to Tiragolumab are similar to those of other ICIs, including fatigue, chills, and nausea (59, 65). The gene discussed is PDCD1; the disease is neoplasm.